BioHarvest Sciences (NASDAQ:BHST) Shares Down 1.3% – Should You Sell?

BioHarvest Sciences Inc. (NASDAQ:BHST) shares fell 1.3% on Friday . The company traded as low as $4.67 and last traded at $4.71. 4,821 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 21,193 shares. The stock had previously closed at $4.77.

Analysts Set New Price Targets

Several equities analysts recently commented on BHST shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday, December 29th. Roth Mkm started coverage on BioHarvest Sciences in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

BioHarvest Sciences Price Performance

The company’s 50 day moving average is $5.01 and its 200 day moving average is $7.30. The company has a current ratio of 1.35, a quick ratio of 1.02 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $77.34 million, a price-to-earnings ratio of -6.93 and a beta of 1.12.

Institutional Trading of BioHarvest Sciences

A number of large investors have recently made changes to their positions in the company. True North Advisors LLC grew its stake in BioHarvest Sciences by 676.1% during the 3rd quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock worth $1,581,000 after buying an additional 146,365 shares during the last quarter. King Luther Capital Management Corp acquired a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $208,000. Geode Capital Management LLC purchased a new position in shares of BioHarvest Sciences during the fourth quarter worth approximately $61,000. Thompson Siegel & Walmsley LLC purchased a new position in shares of BioHarvest Sciences during the fourth quarter worth approximately $1,945,000. Finally, HRT Financial LP acquired a new position in shares of BioHarvest Sciences in the 4th quarter valued at $75,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.